Bio-Plexus Announces Agreement With Fresenius Medical Care, North America.Business Editors & Health/Medical Writers BIOWIRE2K VERNON, Conn.--(BW HealthWire)--Dec. 20, 2000 Bio-Plexus, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BPLX) today announced a development and licensing option agreement with Fresenius Medical Care Fresenius Medical Care is a German company specializing in the production of medical supplies, primarily to facilitate or aid renal dialysis. It is 37%-owned by the health care company Fresenius SE. , North America (FMCNA FMCNA Fresenius Medical Care North America FMCNA Free Methodist Church of North America ) of Lexington, Massachusetts. The agreement would grant a worldwide license of PUNCTUR-GUARD(R) blunting technology for use in developing and marketing Extracorporeal Therapy needles on an exclusive basis. Extracorporeal Therapy needles include those utilized to access a patient's blood vessel for kidney dialysis and liver assist therapies, among others. "We are excited that FMCNA shares our commitment to healthcare worker safety. PUNCTUR-GUARD(R) internal blunting technology, when applied to Extracorporeal Therapy needles, yields a simple safety solution for potentially one of the most problematic needlestick risks to healthcare workers," according to Jack Polidoro, Director of Technology and New Business Development at Bio-Plexus. "Fresenius is pleased to team with Bio-Plexus in developing new PUNCTUR-GUARD(R) based Extracorporeal Therapy needles. We are excited about the potential for bringing a new level of needlestick safety to the dialysis market," said Robert Farrell, Vice President, Strategic Business Development, Fresenius Medical Care, North America. Bio-Plexus welcomes FMCNA to the PUNCTUR-GUARD(R) family. PUNCTUR-GUARD(R) has been proven in both independent studies and clinical use to dramatically reduce needlestick injuries over regular needles. FMCNA, the market leader in dialysis products, joins other market leaders who have development/license agreements with Bio-Plexus to offer new PUNCTUR-GUARD(R) based safety needle devices. Fresenius Medical Care AG is the world's largest integrated provider of products and services for individuals with chronic kidney failure Chronic Kidney Failure Definition Chronic kidney failure occurs when disease or disorder damages the kidneys so that they are no longer capable of adequately removing fluids and wastes from the body or of maintaining the proper level of certain , a condition that affects more than 1,000,000 individuals worldwide. Through its network of approximately 1,240 dialysis clinics in North America, Europe, Latin America and Asia-Pacific, Fresenius Medical Care provides dialysis treatment to approximately 90,200 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Bio-Plexus, Inc. (NASDAQ: BPLX), designs, develops, manufactures and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD(R), DROP-IT(R), and PUNCTUR-GUARD REVOLUTION(TM) brand names. For independent evaluation refer to the Centers for Disease Control (January 1997) and ECRI ECRI European Commission against Racism and Intolerance ECRI Emergency Care Research Institute ECRI Economic Cycle Research Institute , (Health Devices, June 1998 and October 1999) studies. Bio-Plexus has licensed PUNCTUR-GUARD(R) technology to Johnson & Johnson Medical, a division of Ethicon Endo-Surgical, a Johnson & Johnson (NYSE NYSE See: New York Stock Exchange :JNJ JNJ Johnson and Johnson (stock symbol) JNJ Journal of Nursing Jocularity ) company for IV Catheters and TFX TFX Tactical Fighter Experimental TFX Toxic Effects TFX Tactical Field Exercise (also abbreviated TFE) TFX Thin Form Factor TFX Transitions and Effects Medical, a subsidiary of Teleflex Incorporated (NYSE:TFX) for PICC PICC Peripherally-inserted central catheter Critical care An IV catheter inserted in the superior vena cava for long-term infusion of bolus or continuous delivery of therapeutics or TPN–drugs, fluids, nutrients, chemotherapy. Cf Catheter. Introducers. TFX has an exclusive distribution agreement with Bard (NYSE:BCR BCR B Cell Receptor BCR Business Communications Review (magazine) BCR Banca Comerciala Romana (Romanian bank) BCR Breakpoint Cluster Region BCR Benefit/Cost Ratio BCR Bay City Rollers ) for this product. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and Hepatitis B and C. NOTE: THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS AS DEFINED UNDER FEDERAL SECURITIES LAWS, AS AMENDED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF SUCH TERMINOLOGY AS "BELIEVES," "EXPECTS," "MAY," "WILL," "SHOULD," "ANTICIPATES" OR DERIVATIONS OR NEGATIVES THEREOF OR COMPARABLE TERMINOLOGY, OR DISCUSSIONS OF STRATEGY THAT INVOLVES RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF, AMONG OTHER FACTORS, GENERAL ECONOMIC CONDITIONS AND GROWTH IN THE SAFETY MEDICAL PRODUCTS INDUSTRY, COMPETITIVE FACTORS AND PRICING PRESSURES, CHANGES IN PRODUCT MIX, PRODUCT DEMAND, RISK OF DEPENDENCE ON THIRD PARTY SUPPLIERS AND FINANCIERS, ABILITY TO OBTAIN FINANCING, AS WELL AS OTHER FACTORS DESCRIBED FROM TIME TO TIME IN THE COMPANY'S PERIODIC REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER PRESS RELEASES ISSUED BY THE COMPANY. 2000 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion